Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $54.9 million.

  • Nurix Therapeutics' Accumulated Expenses rose 4437.02% to $54.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was $54.9 million, marking a year-over-year increase of 4437.02%. This contributed to the annual value of $54.9 million for FY2025, which is 4437.02% up from last year.
  • As of Q4 2025, Nurix Therapeutics' Accumulated Expenses stood at $54.9 million, which was up 4437.02% from $44.0 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Accumulated Expenses peaked at $54.9 million during Q4 2025, and registered a low of $7.7 million during Q2 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $22.2 million (2022), whereas its average is $24.8 million.
  • In the last 5 years, Nurix Therapeutics' Accumulated Expenses surged by 15702.01% in 2022 and then tumbled by 832.57% in 2023.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Accumulated Expenses stood at $14.5 million in 2021, then skyrocketed by 54.15% to $22.4 million in 2022, then increased by 11.33% to $25.0 million in 2023, then surged by 52.16% to $38.0 million in 2024, then surged by 44.37% to $54.9 million in 2025.
  • Its Accumulated Expenses stands at $54.9 million for Q4 2025, versus $44.0 million for Q3 2025 and $37.0 million for Q2 2025.